Search Results - "Weickhardt, A"

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer by Weickhardt, A J, Williams, D S, Lee, C K, Chionh, F, Simes, J, Murone, C, Wilson, K, Parry, M M, Asadi, K, Scott, A M, Punt, C J A, Nagtegaal, I D, Price, T J, Mariadason, J M, Tebbutt, N C

“…Background: Bevacizumab prolongs progression-free survival (PFS) in patients with metastatic colorectal cancer. We analysed the protein expression levels of…”
Get full text

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer by Price, T J, Bruhn, M A, Lee, C K, Hardingham, J E, Townsend, A R, Mann, K P, Simes, J, Weickhardt, A, Wrin, J W, Wilson, K, Gebski, V, Van Hazel, G, Robinson, B, Cunningham, D, Tebbutt, N C

“…Background: Mutations affecting RAS genes are now established predictive markers of nonresponse to anti-EGFR antibodies in advanced CRC. This analysis assessed…”
Get full text

Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC) by Anton, A., Wong, S., Parente, P., Azad, A., Shapiro, J.A., Weickhardt, A., Torres, J., Parnis, F., Goh, J., Semira, C., Gibbs, P., Tran, B., Pezaro, C.

Get full text

Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis by Seidel, C., Schaefers, C., Connolly, E.A., Weickhardt, A., Grimison, P., Wong, V., De Giorgi, U., Hentrich, M., Zschäbitz, S., Ochsenreither, S., Vincenzi, B., Oing, C., Bokemeyer, C., Engel, N., Alsdorf, W., Tran, B.

“…In relapsed or refractory (RR) metastatic germ cell cancer (GCC), high-dose (HD) chemotherapy (CTX) plus autologous stem cell transplantation is considered the…”
Get full text

2586 Pattern of presentation of brain metastases (BM) in metastatic renal cell cancer (mRCC) patients (pts) treated with targeted therapies (TT): Implications for screening practice by Spain, L, Dowling, A, Kwan, E, Pezaro, C, Dai, D, Chia, P, Tran, B, Pook, D, Weickhardt, A

Get full text

Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway by Weickhardt, Andrew J, Tebbutt, Niall C, Mariadason, John M

“…Mutations in K-Ras are observed in approximately 40% of colon tumours. This has significant implications for predicting likelihood of response to the…”
Get more information

Mechanisms of acquired resistance to the fibroblast growth factor receptor (FGFR) inhibitor BGJ398 in FGFR driven bladder cancer by Hodgson-Garms, M., Mariadason, J., Weickhardt, A.

Get full text

Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer by Bowles, D W, Weickhardt, A, Jimeno, A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are valuable treatments for EGFR-mutated non-small cell lung cancer (NSCLC)…”
Get full text

72 (PB060): TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations by Loriot, Y., Zhang, A., Hansen, A., Mantia, C., Boni, V., Weickhardt, A., Yu, E.Y., Robert, M., Iyer, G., Murtha, A., Owens, S., Suttle, B., Vandekerkhove, G., Wyatt, A., Gammon, G., Burn, T., Tran, B.

Get full text

500LBA LBA Orals: Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301) by Tran, B., Boni, A., Hansen, A., Boni, V., Mantia, C., Yu, E., Weickhardt, A., Robert, M., Gupta, S., Necchi, A., Morales-Barrera, R., Hoimes, C., Berlin, J., Iyer, G., Millward, M., Burn, T., Lihou, C., Gammon, G., Rosenberg, J., Loriot, Y.

Get full text

35 (PB023): A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301) by Zhang, A., Boni, V., Hanson, A., Mantia, C., Weickhardt, A., Yu, E., Gupta, S., Robert, M., Iyer, G., Millward, M., Morales-Barrera, R., Hoimes, C., Berlin, J., Mittal, K., Hill, A., Racca, F., Pouessel, D., Lihou, C., Tran, B., Loriot, Y.

Get full text

Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer by Bowles, D W, Weickhardt, A, Jimeno, A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are valuable treatments for EGFR-mutated non-small cell lung cancer (NSCLC)…”
Get full text

A Prospective Study of F-18 Fluoro-methyl-choline (FCH) And Ga-68 HBED-CC- (PSMA) in Men being Considered for Salvage Radiation Treatment for Biochemical Failure Post Radical Prostatectomy by Bauman, G.S., Metser, U., Scott, A., Pouliot, F., Weickhardt, A., Davis, I., Hicks, R., Punwani, S., Chua, S., Emmett, L.

Get full text

226P Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC) by Jensen, A., Karunaratna, N., Wong, S., Shapiro, J., Weickhardt, A., Spain, L., Azad, A.A., Kwan, E., Muthusamy, A., Torres, J., Parente, P., Francis, P., Parnis, F.X., Goh, J., Gibbs, P., Tran, B., Anton, A.

Get full text

220PExamining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC) by Anton, A, Wong, S, Parente, P, Azad, A, Shapiro, J A, Weickhardt, A, Torres, J, Parnis, F, Goh, J, Semira, C, Gibbs, P, Tran, B, Pezaro, C

Get full text

Crizotinib for the treatment of patients with advanced non-small cell lung cancer by Bowles, D W, Weickhardt, A J, Doebele, R C, Camidge, D R, Jimeno, A

“…Crizotinib is a potent small-molecule inhibitor of ALK tyrosine kinase receptor (anaplastic lymphoma kinase; ALK) and hepatocyte growth factor receptor (HGF…”
Get full text

Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a general tertiary centre by Ha, F.J., Weickhardt, A.J., Parakh, S., Glassford, N.J., Warrillow, S., Jones, D.

Get full text

Pembrolizumab with ChemoRadiotherapy for Muscle Invasive Bladder Cancer: the ANZUP PCR-MIB trial by Weickhardt, A.J., Foroudi, F., Sengupta, S., Grimison, P., Patanjali, N., Leslie, S., Ng, S., Tang, C., Goodwin, R., Hovey, E., Jarvis, T., Chen, C., Herschtal, A., Galletta, L., Sandhu, S., Tai, K.-H., Lawrentschuk, N., Davis, I.

Get full text

Pten and Advanced Colorectal Cancer (CRC): Analysis from the Phase III Agitg Max Trial of Capecitabine Alone or in Combination with Bevacizumab +/- Mitomycin C by Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., Weickhardt, A., Simes, R.J., Munroe, C., Tebbutt, N.

Get full text

532P - Pten and Advanced Colorectal Cancer (CRC): Analysis from the Phase III Agitg Max Trial of Capecitabine Alone or in Combination with Bevacizumab +/- Mitomycin C by Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., Weickhardt, A., Simes, R.J., Munroe, C., Tebbutt, N.

“…The tumour suppressor gene PTEN may have a role as a biomarker for anti-EGFR therapy in CRC. As PTEN expression also has a relationship with VEGF expression…”
Get full text